Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2020 - 2022)

Atea Pharmaceuticals has reported Other Non-Current Liabilities over the past 3 years, most recently at $5.2 million for Q3 2022.

  • Quarterly results put Other Non-Current Liabilities at $5.2 million for Q3 2022, changed N/A from a year ago — trailing twelve months through Sep 2022 was $5.2 million (changed N/A YoY), and the annual figure for FY2021 was $5.9 million, up 16377.78%.
  • Other Non-Current Liabilities for Q3 2022 was $5.2 million at Atea Pharmaceuticals, down from $6.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for AVIR hit a ceiling of $6.0 million in Q2 2022 and a floor of $29000.0 in Q2 2021.
  • Median Other Non-Current Liabilities over the past 3 years was $2.6 million (2021), compared with a mean of $2.9 million.
  • Peak annual rise in Other Non-Current Liabilities hit 20617.24% in 2022, while the deepest fall reached 5149.56% in 2022.
  • Atea Pharmaceuticals' Other Non-Current Liabilities stood at $36000.0 in 2020, then surged by 16377.78% to $5.9 million in 2021, then dropped by 12.85% to $5.2 million in 2022.
  • The last three reported values for Other Non-Current Liabilities were $5.2 million (Q3 2022), $6.0 million (Q2 2022), and $5.9 million (Q1 2022) per Business Quant data.